Cartesian Therapeutics (RNAC) Research & Development (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Research & Development of $19.5 million for Q1 2026, up 32.64% year-over-year from $14.7 million in Q1 2025, and up 32.5% quarter-over-quarter from $14.7 million in Q4 2025.
Cartesian Therapeutics (RNAC) Research & Development (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Research & Development for 12 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 32.64% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $62.8 million (up 25.54% YoY), while the FY2025 annual figure was $58.0 million, up 28.66% from the prior year.
- Research & Development rose to $19.5 million in Q1 2026 per RNAC's latest filing, from $14.7 million in the prior quarter.
- Across five years, Research & Development topped out at $21.9 million in Q4 2023 and bottomed at $9.7 million in Q1 2024.
- Historically, Research & Development has averaged $15.7 million across 5 years, with a median of $14.9 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development slumped 48.26% — and 2025, when it surged 50.69%.
- Cartesian Therapeutics' Research & Development stood at $19.0 million in 2022, then rose by 15.21% to $21.9 million in 2023, then plunged by 48.26% to $11.3 million in 2024, then increased by 29.92% to $14.7 million in 2025, then surged by 32.5% to $19.5 million in 2026.
- Business Quant data shows RNAC's Research & Development at $19.5 million in Q1 2026, $14.7 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 20.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.43 Mn |
| Mar 31, 2026 | 19.46 Mn |
| Dec 31, 2025 | 14.69 Mn |
| Sep 30, 2025 | 13.80 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 14.67 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Sep 30, 2024 | 11.40 Mn |
| Jun 30, 2024 | 12.66 Mn |
| Mar 31, 2024 | 9.74 Mn |
| Dec 31, 2023 | 21.85 Mn |
| Sep 30, 2023 | 13.00 Mn |
| Jun 30, 2023 | 17.78 Mn |
| Mar 31, 2023 | 18.62 Mn |
| Dec 31, 2022 | 18.97 Mn |
| Sep 30, 2022 | 16.54 Mn |
| Jun 30, 2022 | 19.18 Mn |
| Mar 31, 2022 | 17.69 Mn |
| Dec 31, 2021 | 20.32 Mn |
| Sep 30, 2021 | 20.95 Mn |